<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05612568</url>
  </required_header>
  <id_info>
    <org_study_id>S64110</org_study_id>
    <nct_id>NCT05612568</nct_id>
  </id_info>
  <brief_title>5 Years of Eye Screening for ARF in Children Aged &lt;3 Years in Flanders</brief_title>
  <official_title>Five Years of Eye Screening for Amblyopia Risk Factors in Children Aged &lt;3 Years in Flanders: Epidemiological Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen KU Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research we will investigate the distribution and evolution of amblyopia risk factors&#xD;
      and other refractive errors in children younger than 3 years of age. The significance and&#xD;
      magnitude of current global evolutions in ARF and refractive errors will be verified to&#xD;
      update current guidelines and practices. Better insight in associated factors of amblyopia&#xD;
      risk factors will contribute to current understanding of amblyopia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The eye screening program of the Flemish governmental agency 'Kind en Gezin' is a&#xD;
      well-implemented screening program for detection of ARF in children under the age of 3 years.&#xD;
      This screening covers almost 85% of all children born in the Flemish community. Valuable&#xD;
      information about distribution and determinants of refractive errors and ARF are collected at&#xD;
      'Kind en Gezin', but remain unstudied until today.&#xD;
&#xD;
      Our aim is to analyze the distribution and evolution of refractive errors in children under&#xD;
      the age of 3 years in Flanders. We suppose that identification of patterns in this&#xD;
      distribution, and identification of determinants that influence ARF, will lead to improved&#xD;
      knowledge about amblyopia (risk factors) and on their turn help optimize the ARF screening&#xD;
      program. Evaluation of the distribution and evolution of refractive errors over time, and&#xD;
      comparison with global results, will also give us insight in the significance of the myopia&#xD;
      epidemic in Flanders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Refractive error per eye</measure>
    <time_frame>during single-visit screening</time_frame>
    <description>Sphere, cylinder, spherical equivalent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in refractive error between both eyes</measure>
    <time_frame>during single-visit screening</time_frame>
    <description>Sphere OD-OS, cylinder OD-OS, spherical equivalent OD-OS</description>
  </primary_outcome>
  <enrollment type="Anticipated">250000</enrollment>
  <condition>Amblyopia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        We include all children with a PlusOptix screening between 2013 and 2018 with the age of&#xD;
        12±1 months or 30±1 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  We include all children with a PlusOptix screening between 2013 and 2018 with the age&#xD;
             of 12±1 months or 30±1 months. Children who were screened twice, can be included twice&#xD;
             with both screening results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Months</minimum_age>
    <maximum_age>31 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 3, 2022</last_update_submitted>
  <last_update_submitted_qc>November 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

